M
Martin Wilhelm
Researcher at Paracelsus Private Medical University of Salzburg
Publications - 164
Citations - 10031
Martin Wilhelm is an academic researcher from Paracelsus Private Medical University of Salzburg. The author has contributed to research in topics: T cell & Transplantation. The author has an hindex of 43, co-authored 159 publications receiving 8932 citations. Previous affiliations of Martin Wilhelm include Boston Medical Center & University of Würzburg.
Papers
More filters
Journal ArticleDOI
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
Andreas Engert,Annette Plütschow,Hans Theodor Eich,Andreas Lohri,Bernd Dörken,Peter Borchmann,Bernhard Berger,Richard Greil,Kay C. Willborn,Martin Wilhelm,Jürgen Debus,Michael J. Eble,Martin Sökler,A. D. Ho,Andreas Rank,Arnold Ganser,Lorenz Trümper,Carsten Bokemeyer,Hartmut Kirchner,Jörg Schubert,Zdenek Kral,Michael Fuchs,Hans Konrad Müller-Hermelink,Rolf-Peter Müller,Volker Diehl +24 more
TL;DR: In patients with early-stage Hodgkin's lymphoma and a favorable prognosis, treatment with two cycles of ABVD followed by 20 Gy of involved-field radiation therapy is as effective as, and less toxic than, four cycles ofABVD following by 30 Gy ofinvolved- field radiation therapy.
Journal ArticleDOI
Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma
TL;DR: Results show that aminobisphosphonates stimulating γδ T cells have pronounced effects on the immune system, which might contribute to the antitumor effects of these drugs.
Journal ArticleDOI
γδ T cells for immune therapy of patients with lymphoid malignancies
Martin Wilhelm,Volker Kunzmann,Susanne Eckstein,Peter Reimer,Florian Weissinger,Thomas Ruediger,Hans-Peter Tony +6 more
TL;DR: This clinical trial demonstrates, for the first time, that gammadelta T-cell-mediated immunotherapy is feasible and can induce objective tumor responses.
Journal ArticleDOI
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier,Barbara Pro,H. Miles Prince,Francine M. Foss,Lubomir Sokol,Matthew Greenwood,Dolores Caballero,Peter Borchmann,Franck Morschhauser,Martin Wilhelm,Lauren Pinter-Brown,Swaminathan Padmanabhan,Andrei R. Shustov,Jean Nichols,Susan Carroll,John Balser,Barbara Balser,Steven M. Horwitz +17 more
TL;DR: Single-agent romidepsin induced complete and durable responses with manageable toxicity in patients with relapsed or refractory peripheral T-cell lymphoma across all major PTCL subtypes, regardless of the number or type of prior therapies.
Journal ArticleDOI
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
Claus Rödel,Claus Rödel,Ullrich Graeven,Rainer Fietkau,Werner Hohenberger,Torsten Hothorn,Torsten Hothorn,Dirk Arnold,Ralf-Dieter Hofheinz,Michael Ghadimi,Hendrik A. Wolff,Marga Lang-Welzenbach,Hans-Rudolf Raab,Christian Wittekind,Philipp Ströbel,Ludger Staib,Martin Wilhelm,Gerhard G. Grabenbauer,Hans Hoffmanns,Fritz Lindemann,Anke Schlenska-Lange,Gunnar Folprecht,Rolf Sauer,Torsten Liersch +23 more
TL;DR: In this paper, the authors compared the previously established regimen with an investigational regimen in which oxaliplatin was added to both preoperative chemoradiotherapy and postoperative chemotherapy.